The U.S. government in 2016 spent around $29 billion on prescription drugs in Medicare's Part B, which includes most injectable drugs, and nearly $100 billion in Part D, which covers as pills and other drugs usually dispensed in pharmacies. Trump is also consi...
On September 20, 2024, the Centers for Medicare & Medicaid Services (CMS) released the long-awaitedfinal ruleaddressing several important drug pricing matters under the Medicaid Drug Rebate Program (MDRP) (Final Rule). The Final Rule’s provisions also have significant ...
Medicarenegotiationsfinancial toxicitypolicyPrescription drug costs within oncology remain a challenge for many patients with cancer. The Mark Cuban Cost Plus Drug Company (MCCPDC) launched in 2022, aiming to provide transparently priced medications at reduced costs. In this study, we sought to ...
recommends legislation and regulatory reforms that would promote safe prescription drug importation and implement a most favored nation system of drug pricing for Medicare. The recommendations are based on executive orders from the Trump administration and Democratic legislation from the previous Congress. ...
Discusses Medicare overpayments to physicians for drugs such as chemotherapeutic agents which are administered to patients in the outpatient setting. Argument of oncologists that they are underpaid for their professional services and practice expenses, so it should not be an issue that they purchase dr...
Medicarenegotiationsfinancial toxicitypolicyPrescription drug costs within oncology remain a challenge for many patients with cancer. The Mark Cuban Cost Plus Drug Company (MCCPDC) launched in 2022, aiming to provide transparently priced medications at reduced costs. In this study, we sought to ...
A new proposal from the Trump administration is targeting secretive rebates between drug manufacturers, insurers and pharmacy benefits managers as a way to lower drug prices for Medicare. A proposed rule released Thursday would scale back the legal prote
Medicare Part D is optional, but if you don’t opt in, then you won’t be eligible for reduced pricing that may be negotiated by Medicare for some high-cost drugs. Other Prescription Cost Reduction Measures In addition to the ability to negotiate prices, the IRA also requires any pharmaceut...
Medicare reveals results of drug price negotiations The first round of pricing talks under new powers granted to the U.S. government involved drugs like the blood thinners Eliquis and Xarelto, as well immune medicines like Enbrel and Stelara. ...
Advising clients on implementation of the historic Medicare drug price negotiation and new drug pricing policy changes passed as part of the IRA of 2022 The prescription drug pricing provisions of the Inflation Reduction Act of 2022 (IRA) represent a historic transformation of Medicare drug pricing ...